

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Decreasing Case-Fatality But Not Death Following Admission to ICUs in Australia, 2005-2018

To the Editor:

Death is the most common outcome measure used in observational and interventional studies in critical care medicine.¹ Death, as an outcome measure, has the merits of being an objective, binary, and clinically relevant variable and may be expressed as a case-fatality (deaths per 100 cases, percentage) or as a mortality rate (deaths per 100,000 population). Although related by the numerator of each as number of deaths, the denominators differ with associated interpretive implications. Although conditions with high case-fatality (ie, rabies, >99%) have major implications for affected patients, they will be associated with low

mortality rates when occurrence is rare. On the other hand, conditions with low overall case-fatality (ie, coronavirus disease 2019 [COVID-19], <5%) may be associated with devastating mortality rates in a pandemic setting.

Numerous studies conducted in ICUs have reported that the survival outcome associated with critical illness has improved over the past several decades.²⁻⁷ Because few new therapeutic interventions or strategies have been demonstrated to reduce mortality rates effectively, these observations have been attributed partially to general improvements in quality of care.⁸ When outcomes from critical illness and evaluating trends are reported over time, it is important to consider the differences between case-fatality and mortality rates in drawing conclusions. We therefore sought to examine the case-fatality and mortality rates associated with admission to ICUs in Australia between 2005 and 2018 to evaluate whether the outcome of critical illness may be changing.

Patients and Methods

A population-based cohort of all admissions to Australians among residents \geq 20 years old registered in the Australian and New Zealand Intensive Care Society Adult Patient Database between 2005 and 2018 was assembled. The Australian and New Zealand Intensive Care Society Adult Patient Database is a well-established database that is estimated to include >90% of admissions to Australian ICUs and has been described in detail previously.⁹ This study was approved with waiver of individual informed consent by The Alfred Hospital Human Research Ethics Committee (No. 693/19).

Basic demographics (age and sex), hospital admission and discharge dates, discharge vital status, and Australia and New

Results

During the 14-year study period, there were 1,545,395 first admissions to ICUs among Australian adult residents. Among these, 130,084 patients died within 30 days, which corresponds to a case-fatality of 8.42% and an adjusted mortality rate of 57.21 per 100,000 population. The median age of this cohort was 65.5 years (interquartile range, 51.7 to 75.7), 890,081 (57.61%; n = 1,544,972) were men; the median ANZROD score was 1.82% (ie, 1.82% risk for death; interquartile range, 0.57% to 7.35%).

Zealand risk of death (ANZROD) score were obtained for each admission.¹⁰ Only a patient's first admission was included. Deaths at 30-days after the admission date were identified. Patients who were discharged from hospital alive prior to 30 days were classified as survivors. Case-fatality was calculated by the number of deaths at 30 days per 100 admissions and was reported as a percent. The number of admissions and 30-day deaths were used to calculate incidence and mortality rates per 100,000 population, respectively. These were further adjusted by directly standardizing annual rates by sex and age (in 5-year strata from ages 20 to 85 years and then \geq 85 years) referenced to the Australian 2016 national population. Analysis was descriptive.

The case-fatality associated with ICU admission decreased by more than one-third between 2005 (10.96%) and 2018 (6.88%) (Fig 1). The decreasing annual case-fatality was mirrored by an increase in the adjusted incidence of admissions (Fig 1). Although there was moderate year-to-year variability with a peak in 2005 (59.84 per 100,000) and nadir in 2013 (54.46 per 100,000), no evident consistent linear trend in the adjusted annual mortality rates occurred during the study years as shown in Figure 1.




Figure 1 – Annual case-fatality and mortality rate associated with admission to Australian ICUs, 2005-2018.




Figure 2 - Age- and sex-adjusted admission incidence and mortality rate by quartiles of Australia and New Zealand Risk of Death scores, 2005-2018.

TABLE 1	Influence of	Testing or	Admission	Frequency	on Case Fata	lity and Mo	ortality Rate ^a
---------	--------------	------------	-----------	-----------	--------------	-------------	----------------------------

Variable	Example A ^b	Example B ^c	Example C ^d	
Admissions or cases (baseline)	1,000 high risk	1,000 high risk plus 1,000 low risk	1,000 high risk plus 10,000 low risk	
Case fatality	100/1,000 = 10%	$\begin{array}{l} 100/1,000 \text{ plus } 10/1,000;\\ 110/2,000 = 5.5\% \end{array}$	100/1,000 plus 100/10,000; 200/11,000 = 1.8%	
Mortality rate	100/100,000	110/100,000	200/100,000	
Admissions or cases (preventive intervention to reduce disease by 50%)	$\begin{array}{l} 50\% \times 1,000 \text{ high} \\ \text{risk} = 500 \end{array}$	$50\% \times (1,000 \text{ high risk plus} \\ 1,000 \text{ low risk}) = 1,000$	$50\% \times$ (1,000 high risk plus 10,000 low risk) = 5,500	
Case fatality	50/500 = 10%	50/500 plus 5/500; 55/ 1,000 = 5.5%	50/500 plus 50/5,000; 100/5,500 = 1.8%	
Mortality rate	50/100,000	55/100,000	100/100,000	

^aHypothetical example with population of 100,000 residents; true risk for death 1% of low-risk and 10% for high-risk cases; at baseline and after implementation of a preventive intervention that reduced cases by 50%.

^bOnly high-risk cases admitted or tested.

^cHigh-risk and some low-risk cases admitted or tested.

^dHigh-risk and many low-risk cases admitted or tested.

Increasing adjusted incidence of admission during the study period occurred proportionally across quartiles of ANZROD scores (Fig 2). The adjusted annual mortality rates for the first (lowest), second, third, and fourth (highest) quartiles of ANZROD scores were 0.34, 1.24, 6.08, and 48.68 per 100,000, respectively, and these were similar throughout the study (Fig 2).

Discussion

In this study, we demonstrate that the case-fatality has decreased progressively but that the mortality rate associated with admissions to ICUs in Australia between 2005 and 2018 has not. This is an important observation, because readers of medical literature may not recognize or appreciate the important differences between case-fatality and mortality rate. However, this is becoming increasingly topical related to the current COVID-19 pandemic. Issues surrounding large variations in case-fatality between countries and in relation to population differences and testing rates have been presented in the medical literature and the lay press. It may be expected that, as compared to a region with a restrictive testing policy for high-risk patients, a region that has higher testing rates for COVID-19, especially inclusive of asymptomatic or younger healthy individuals who are low risk for death, will have a lower case-fatality but comparable mortality rate. An illustrative hypothetical example is shown in Table 1.

There is no preferred measure of death outcome; use of case-fatality or mortality rates remain dependent on the study objective. On one hand, case-fatality is generally a preferred measure for expressing the severity of an illness, is clinically relevant for patient care, and may be used as an outcome in clinical trials. On the other hand, mortality rate is superior for evaluating the burden of an illness and, unlike case-fatality, is responsive to preventative measures (Table 1).

In summary, this letter highlights the importance of differentiating case-fatality and mortality rate. These data suggest that, although there have been significant successes in critical care management in Australia with improved case-fatality, the death burden has not changed appreciably. Our data support the precise use of the terms case-fatality and death and argue for careful interpretation of studies that aim to define the burden of a disease or examine changes in outcome over time.

Kevin B. Laupland, MD Brisbane, QLD, Australia Alexis Tabah, MD Redcliffe, QLD, Australia Anthony D. Holley, MBBS Judith Bellapart, MD, PhD Brisbane, QLD, Australia David V. Pilcher, MBBS Prahran, VIC, Australia

AFFILIATIONS: From the Department of Intensive Care Services (K. Laupland, A. Holley, and J. Bellapart), Royal Brisbane and Women's Hospital, the Queensland University of Technology (K. Laupland); the Faculty of Medicine (A. Tabah, A. Holley, and J. Bellapart), University of Queensland; the Intensive Care Unit (A. Tabah), Redcliffe Hospital; and the Department of Intensive Care (D. Pilcher), The Alfred Hospital, Prahran; the ANZICS Centre for Outcome and Resource Evaluation (D. Pilcher), Carlton South, VIC, Australia; and The Australian and New Zealand Intensive Care -

Research Centre (D. Pilcher), School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

FINANCIAL/NONFINANCIAL DISCLOSURES: None declared. CORRESPONDENCE TO: Kevin B. Laupland MD; e-mail: Kevin. laupland@qut.edu.au

Copyright o 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

DOI: https://doi.org/10.1016/j.chest.2020.11.059

Acknowledgments

Author contributions: Study conception and design (K. Laupland); data acquisition (D. Pilcher, A. Tabah, K. Laupland); analysis (K. Laupland); interpretation of data (all authors); article drafting (K. Laupland), article revision for important intellectual content (all authors); final approval of the version submitted for publication (all authors); agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved (K. Laupland, D. Pilcher).

Other contributions: The authors and the ANZICS CORE management committee would like to thank clinicians, data collectors and researchers at the ICUs at the following contributing sites: Albury Wodonga Health; Alfred Hospital; Alice Springs Hospital; Allamanda Private Hospital; Angliss Hospital; Armadale Health Service; Armidale Rural Referral Hospital; Ashford Community Hospital; Austin Hospital; Ballarat Health Services; Bankstown-Lidcombe Hospital; Bathurst Base Hospital; Bendigo Health Care Group; Blacktown Hospital; Box Hill Hospital; Brisbane Private Hospital; Brisbane Waters Private Hospital; Buderim Private Hospital; Bunbury Regional Hospital; Bundaberg Base Hospital; Caboolture Hospital; Cabrini Hospital; Cairns Hospital; Calvary Hospital (Canberra); Calvary Hospital (Lenah Valley); Calvary John James Hospital; Calvary Mater Newcastle; Calvary North Adelaide Hospital; Calvary Wakefield Hospital (Adelaide); Campbelltown Hospital; Canberra Hospital; Central Gippsland Health Service (Sale); Coffs Harbour Health Campus; Concord Hospital (Sydney); Dandenong Hospital; Dubbo Base Hospital; Epworth Eastern Private Hospital; Epworth Freemasons Hospital; Epworth Geelong; Epworth Hospital (Richmond); Fairfield Hospital; Figtree Private Hospital; Fiona Stanley Hospital; Flinders Medical Centre Flinders Private Hospital; Footscray Hospital; Frankston Hospital; Fremantle Hospital; Gold Coast Private Hospital; Gold Coast University Hospital; Gosford Hospital; Gosford Private Hospital; Goulburn Base Hospital; Goulburn Valley Health; Grafton Base Hospital; Greenslopes Private Hospital; Griffith Base Hospital; Hervey Bay Hospital; Hollywood Private Hospital; Holmesglen Private Hospital; Hornsby Ku-ring-gai Hospital; Hurstville Private Hospital; Ipswich Hospital; John Fawkner Hospital; John Flynn Private Hospital; John Hunter Hospital; Joondalup Health Campus; Kareena Private Hospital; Knox Private Hospital; Latrobe Regional Hospital; Launceston General Hospital; Lingard Private Hospital; Lismore Base Hospital; Liverpool Hospital; Logan Hospital; Lyell McEwin Hospital; Mackay Base Hospital; Macquarie University Private Hospital; Manly Hospital & Community Health; Manning Rural Referral Hospital; Maroondah Hospital; Mater Adults Hospital (Brisbane); Mater Health Services North Queensland; Mater Private Hospital (Brisbane); Mater Private Hospital (Sydney); Melbourne Private Hospital; Mersey Community Hospital; Mildura Base Hospital; Modbury Public Hospital; Mona Vale Hospital; Monash Medical Centre-Clayton Campus; Mount Hospital; Mount Isa Hospital; Mulgrave Private Hospital; Nambour General Hospital; Nambour Selangor Private Hospital; National Capital Private Hospital; Nepean Hospital; Newcastle Private Hospital; Noosa Hospital; North Shore Private Hospital; North West Regional Hospital (Burnie); Northeast Health Wangaratta; Norwest Private Hospital; Orange Base Hospital; Peninsula Private Hospital; Peter MacCallum Cancer Institute; Pindara Private Hospital; Port Macquarie Base Hospital; Prince of Wales Hospital (Sydney); Prince of Wales Private Hospital (Sydney); Princess Alexandra Hospital; Queen Elizabeth II Jubilee Hospital; Redcliffe Hospital; Repatriation General Hospital (Adelaide); Robina Hospital;

Rockhampton Hospital; Rockingham General Hospital; Royal Adelaide Hospital; Royal Brisbane and Women's Hospital; Royal Darwin Hospital; Royal Hobart Hospital; Royal Melbourne Hospital; Royal North Shore Hospital; Royal Perth Hospital; Royal Prince Alfred Hospital; Shoalhaven Hospital; Sir Charles Gairdner Hospital; South West Healthcare (Warrnambool); St Andrew's Hospital (Adelaide); St Andrew's Hospital Toowoomba; St Andrew's War Memorial Hospital; St George Hospital (Sydney); St George Private Hospital (Sydney); St John of God (Berwick); St John Of God Health Care (Subiaco); St John Of God Hospital (Ballarat); St John of God Hospital (Bendigo); St John Of God Hospital (Geelong); St John Of God Hospital (Murdoch); St John of God Midland Public & Private; St Vincent's Private Hospital Northside; St Vincent's Hospital (Melbourne); St Vincent's Hospital (Sydney); St Vincent's Hospital (Toowoomba); St Vincent's Private Hospital (Sydney); St Vincent's Private Hospital Fitzroy; Sunnybank Hospital; Sunshine Coast University Hospital; Sunshine Hospital; Sutherland Hospital & Community Health Services; Sydney Adventist Hospital; Sydney Southwest Private Hospital; Tamworth Base Hospital; The Bays Hospital; The Chris O'Brien Lifehouse; The Memorial Hospital (Adelaide); The Northern Hospital; The Prince Charles Hospital; The Queen Elizabeth (Adelaide); The Wesley Hospital; Toowoomba Hospital; Townsville University Hospital; Tweed Heads District Hospital; University Hospital Geelong; Wagga Wagga Base Hospital & District Health; Warringal Private Hospital; Werribee Mercy Hospital; Western District Health Service (Hamilton); Western Hospital (SA); Western Private Hospital; Westmead Hospital; Westmead Private Hospital; Wimmera Health Care Group (Horsham); Wollongong Hospital; Wollongong Private Hospital; and Wyong Hospital.

References

- Muscedere JG, Day A, Heyland DK. Mortality, attributable mortality, and clinical events as end points for clinical trials of ventilator-associated pneumonia and hospital-acquired pneumonia. *Clin Infect Dis.* 2010;51(suppl1):S120-S125.
- Timsit JF, Laupland KB. Is the burden of severe sepsis and septic shock changing? Crit Care Med. 2013;41(5):1361-1363.
- 3. Penuelas O, Muriel A, Abraira V, et al. Inter-country variability over time in the mortality of mechanically ventilated patients. *Intensive Care Med.* 2020;46(3):444-453.
- 4. Meyer N, Harhay MO, Small DS, et al. Temporal trends in incidence, sepsis-related mortality, and hospital-based acute care after sepsis. *Crit Care Med.* 2018;46(3):354-360.
- 5. Majumdar A, Bailey M, Kemp WM, Bellomo R, Roberts SK, Pilcher D. Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015. *J Hepatol.* 2017;67(6):1185-1193.
- 6. Darmon M, Bourmaud A, Georges Q, et al. Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. *Intensive Care Med.* 2019;45(7):977-987.
- Karakus A, Haas LEM, Brinkman S, de Lange DW, de Keizer NF. Trends in short-term and 1-year mortality in very elderly intensive care patients in the Netherlands: a retrospective study from 2008 to 2014. *Intensive Care Med.* 2017;43(10):1476-1484.
- 8. Santacruz CA, Pereira AJ, Celis E, Vincent JL. Which multicenter randomized controlled trials in critical care medicine have shown reduced mortality? A systematic review. *Crit Care Med.* 2019;47(12): 1680-1691.
- **9**. Stow PJ, Hart GK, Higlett T, et al. Development and implementation of a high-quality clinical database: the Australian and New Zealand Intensive Care Society adult patient database. *J Crit Care*. 2006;21(2): 133-141.
- **10.** Paul E, Bailey M, Pilcher D. Risk prediction of hospital mortality for adult patients admitted to Australian and New Zealand intensive care units: development and validation of the Australian and New Zealand risk of death model. *J Crit Care.* 2013;28(6):935-941.